CVI Accepts, published online ahead of print on 30 July 2008

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fu, C. Articles by Wang, M. Search for Related Content PubMed PubMed Citation Articles by Fu, C. Articles by Wang, M.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00122-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Effectiveness of live attenuated S₇₉ mumps vaccine against clinical mumps: a matched case-control study

Chuanxi Fu^*, Jianhua Liang, and Ming Wang

Guangzhou Center for Disease Control and Prevention, Guangzhou, China

^* To whom correspondence should be addressed. Email: fuchuanxi{at}gmail.com.

Background: Mumps virus infection is a potentially serious viral infection of childhood and early adulthood. In China, live attenuated S₇₉ mumps vaccine has been licensed for pediatric use since 1990. There has been no assessment of its efficacy. Thus, the objective of this study was to determine the effectiveness of live attenuated S₇₉ mumps vaccine against clinical mumps.

Methods and Materials: Cases were selected from the China Information System for Disease Control and Prevention during Sep 2004 to Mar 2005. Each case was matched to a control by gender, age, and area of residency. In all, 469 cases and 469 controls were enrolled into study. Vaccination information was obtained from the Childrens' EPI Administrative Computerized System. Vaccine effectiveness (VE) was calculated for 1 or 2 doses of S₇₉ vaccine with 95% confidence intervals (CI).

Results: VE of mumps vaccine for 1 dose versus 0 protected 86.0% (95%CI, 77.2%91.5%) of recipients, and VE was much higher in the first 4 years than in the 5-12 years after vaccination.

Conclusion: S₇₉ vaccine can effectively prevent clinical mumps, and a second dose of mumps vaccine is necessary for the protection of children in China.